Intraperitoneal Chemotherapy for Ovarian Cancer Improves Survival but may be Underused

According to this study: Intraperitoneal chemotherapy used in combination with iv chemotherapy increased three-year survival rates in women with stage III ovarian cancer, compared with iv chemotherapy alone. But those receiving intraperitoneal and iv chemotherapy were more likely to need changes to their treatment regimen because of treatment-related toxicities than those receiving only iv chemotherapy. Although the use of intraperi-toneal and iv chemotherapy together has increased over the past decade, fewer than half of eligible patients receive it.